CHRS
Coherus Oncology, Inc.
-0.02 (-2.05%)1.20USD831K成交股數185M市值–本益比(近四季)3.6股價營收比+39.5%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 14.3M+40% | 12.3M+62% | 12.7M+111% | 11.6M+12% | 10.3M+344% | 7.6M-105% | 6.1M-92% | 10.3M-82% | 2.3M | −165M | 74.6M | 58.7M |
| 營業成本 | 4.2M | 3.8M | 4.0M | 3.7M | 3.4M | 2.7M | 2.7M | 1.8M | 1.4M | −74.0M | 32.7M | 24.8M |
| 毛利 | 10.1M+47% | 8.5M+72% | 8.7M+162% | 7.9M-8% | 6.9M+689% | 4.9M-105% | 3.3M-92% | 8.5M-75% | 869K | −90.5M | 41.9M | 33.9M |
| 毛利率 | 70.4% | 69.0% | 68.3% | 67.8% | 66.9% | 65.1% | 54.9% | 82.4% | 37.7% | 55.0% | 56.1% | 57.7% |
| 研發費用 | 21.4M | 21.5M | 31.0M | 27.3M | 26.3M | 24.4M | 22.1M | 20.6M | 28.4M | 13.0M | 25.6M | 23.3M |
| 銷售管理費用 | 21.0M | 23.1M | 23.6M | 24.9M | 26.0M | 26.0M | 28.1M | 27.5M | 40.2M | −22.1M | 48.2M | 45.1M |
| 營業利益 | −32.3M-29% | −36.2M-20% | −45.9M-2% | −44.3M+12% | −45.5M-33% | −45.4M-44% | −46.9M+46% | −39.6M+15% | −67.8M | −81.5M | −32.0M | −34.5M |
| 營業利益率 | -226.0% | -293.7% | -359.9% | -383.1% | -443.6% | -597.9% | -774.2% | -384.9% | -2,937.0% | 49.5% | -42.9% | -58.8% |
| 稅後淨利 | −20.6M-107% | −38.3M-32% | −37.6M+250% | −35.5M+175% | 298M+189% | −56.6M-29% | −10.8M-73% | −12.9M-70% | 103M | −79.7M | −39.6M | −42.9M |
| 淨利率 | -144.2% | -311.3% | -295.3% | -307.1% | 2,903.9% | -744.4% | -177.6% | -125.5% | 4,457.3% | 48.4% | -53.2% | -73.0% |
| 稀釋 EPS | -0.13-105% | -0.28-111% | -3.40+3678% | -0.31+182% | 2.57+182% | 2.57-484% | -0.09-78% | -0.11-78% | 0.91 | -0.67 | -0.41 | -0.49 |
| 稀釋股數 | 155M | 136M | 117M | 116M | 116M | 116M | 115M | 115M | 113M | 94.2M | 97.7M | 87.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 82.9M | 115M | 88.9M | 103M | 217M | 82.4M | 97.7M | 159M | 260M | 103M | 80.3M | 72.9M |
| 應收帳款 | 13.9M | 22.1M | 17.8M | 9.2M | 5.1M | 60.5M | 168M | 175M | 252M | 261M | 217M | 141M |
| 存貨 | 5.7M | 4.8M | 3.2M | 2.0M | 4.5M | 3.5M | 47.6M | 62.2M | 62.0M | 2.1M | 66.8M | 64.0M |
| 總資產 | 191M | 266M | 258M | 517M | 439M | 371M | 505M | 675M | 764M | 630M | 584M | 470M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 130M | 187M | 197M | 429M | 320M | 555M | 593M | 759M | 845M | 823M | 717M | 644M |
| 股東權益 | 60.8M | 78.6M | 61.0M | 87.8M | 120M | −183M | −88.0M | −84.1M | −81.8M | −193M | −134M | −175M |
| 負債比 | 68.2% | 70.4% | 76.4% | 83.0% | 72.7% | 149.4% | 117.4% | 112.5% | 110.7% | 130.7% | 122.9% | 137.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −57.9M+124% | – | – | – | −25.8M | – | – | −46.8M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | 881K | 300K | 300K | 300K | 400K | 400K | 500K | 600K | −700K | 800K | 800K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 42.2M
| Toripalimab | 40.8M | 96.8% | +113.5% |
|---|---|---|---|
| Product And Service Other | 1.3M | 3.2% | -81.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 42.2M | +59.8% | 168M | 398.4% | 1.43 | – |
| FY2024 | 26.4M | +2066.6% | 28.5M | 108.0% | 0.25 | – |
| FY2023 | 1.2M | -99.4% | −238M | -19,531.4% | -2.53 | −175M |
| FY2022 | 211M | -35.4% | −292M | -138.2% | -3.76 | −243M |
| FY2021 | 327M | -31.4% | −287M | -87.9% | -3.81 | −38.7M |
| FY2020 | 476M | +33.6% | 132M | 27.8% | 1.62 | 147M |
| FY2019 | 356M | – | 89.8M | 25.2% | 1.23 | 26.5M |
| FY2018 | 0.00 | – | −209M | –% | -3.22 | −160M |